2-hexyl-4-Pentynoic Acid

2-hexyl-4-Pentynoic Acid

Catalog Number:
L002371350APE
Mfr. No.:
APE-B5969
Price:
$180
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          2-hexyl-4-Pentynoic Acid is a potent and robust inhibitor of HDAC with IC50 value of 13 μM [1]. Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from ε-N-acetyl lysines on histones, allowing the histones to wrap the DNA more tightly. DNA expression is regulated by de-acetylation and acetylation. 2-hexyl-4-Pentynoic Acid, a valproic acid (VPA) derivatives, is a potent and robust HDACs inhibitor. In cerebellar granule cells, 2-hexyl-4-Pentynoic Acid (5 μM) significantly and dose-dependently increased acetylated histone H3 (Ac-H3) levels, and at 50-100 μM led to a maximal increase of 600-700%, compared with only a 200% increase by VPA at 100 μM. 2-hexyl-4-Pentynoic Acid also completely blocked glutamate-induced cell death at 50-100 μM. Also, 2-hexyl-4-Pentynoic Acid restored glutamate-induced neuronal loss. At 50 μM, 2-hexyl-4-Pentynoic Acid effectively increased HSP70-1a and HSP70-1b mRNA levels through HDAC inhibition [1].

      • Properties
        • Alternative Name
          2-(prop-2-yn-1-yl)octanoic acid
          CAS Number
          96017-59-3
          Molecular Formula
          C11H18O2
          Molecular Weight
          182.26
          Appearance
          A colorless liquid
          Purity
          98.00%
          Solubility
          insoluble in H2O; ≥15.45 mg/mL in DMSO; ≥51.8 mg/mL in EtOH
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Zhao J, Chen C, et al. "Identification of HIVEP2 as a dopaminergic transcription factor related to substance use disorders in rats and humans." Transl Psychiatry. 2019 Oct 4;9(1):247. PMID:31586043

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.